Novo CEO Sees Obesity Pill Opening Doors to a New Market in US

Novo Nordisk A/S’s obesity pill will allow it to tap into a massive population of patients that have not yet taken GLP-1s, the drugmaker’s chief executive officer said.

The pill version of its blockbuster obesity shot Wegovy will expand the market for these drugs, CEO Mike Doustdar said at an Endpoints event in San Francisco during the annual JPMorgan Healthcare Conference.